Aralez Announces U.S. Launch Of Zontivity

Aralez Pharmaceuticals (NASDAQ:ARLZ; TSX:ARZ) announced this week will see the commercial launch of Zontivity in the US.
As quoted in the press release:

Zontivity is a once-daily agent indicated for the reduction of thrombotic CV events in patients with a history of myocardial infarction (MI) or in patients with peripheral arterial disease (PAD), and should be used in combination with daily aspirin and/or clopidogrel according to their indications or standard of care.
“We believe Zontivity is a differentiated product that represents a significant opportunity for Aralez as a cornerstone of our cardiovascular franchise,” said Adrian Adams, Chief Executive Officer of Aralez. “We are pleased the initial phased launch team has demonstrated immediate results with an inflection in new prescriptions resulting in a doubling of growth with target physicians in only five weeks post launch, and are excited about the national roll-out this week. We are also pleased with encouraging early indicators for our bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. Zontivity and Yosprala, together with Fibricor®, fully leverage our sales force and positions us nicely for growth.”

Click here to read the full press release.

Source: www.newswire.ca